0.30
—
Close of 4 Nov 2026, in CAD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Pangenomic Health
Its shares trade on Canadian Securities Exchange under the ticker NARA.CN. It has been listed since 18 July 2022.
PanGenomic Health, Inc. operates as a health care platform company. The company is headquartered in Vancouver, British Columbia. The company went IPO on 2022-07-18. The Company, through its subsidiaries, is engaged in developing a self-care digital platform to deliver personalized, evidence-based information about natural treatments. Its products include a mobile app for consumers (Nara), a telehealth mental health app and telehealth platform for consumers (Mindleap) and a clinical decision support platform for health practitioners (MUJN). The Nara mobile app provides consumers with a knowledge base, which is based on individual's user profile, leveraging input from mental health questionnaires, drug treatment regimen, genomic sequencing analysis, as well as their protein and microbiome biomarker reports. The Mindleap platform provides a variety of tools and resources to help individuals understand and improve their inner wellness. The MUJN clinical decision support platform provides health practitioners with access to the consumer's mobile app data and their diagnostic reports.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 18 Jul 2022
- Website
- pangenomic.com ↗
Leadership
Pay as last reported
- Mr. Robert NygrenExecutive Chairman of the Board, since 2021C$150,000
- Ms. Maryam MarissenPresident, Chief Executive Officer, Director, since 2022C$150,000
- Ms. Tammy GillisChief Financial OfficerC$75,000
- Ms. Manpreet DhillonDirector
- Mr. Jerry LaiIR Contact Officer
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Pangenomic Health Inc. offers a self-care digital platform with personalized natural treatment information.
- Nara mobile app integrates genomic sequencing and biomarker reports for tailored health insights.
- MUJN clinical decision support platform connects consumer data with practitioner access.
Weaknesses
- Pangenomic Health Inc. has limited product diversity beyond mental health and genomics.
- The company's reliance on genomic sequencing may restrict market reach to tech-savvy users.
- Vancouver headquarters limits global expansion opportunities in key markets.
Opportunities
- Expanding Nara app to include more natural treatment options could attract broader consumer base.
- Partnerships with healthcare providers in the United States could enhance market penetration.
- Growing interest in mental health services presents a significant opportunity for Mindleap.
Threats
- Competition from established health tech companies could challenge market share.
- Regulatory changes in health data privacy may increase operational costs.
- Economic downturns might reduce consumer spending on non-essential health apps.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.